Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alfa-2b in JAK2V617F-positive PV and ET: molecular response cohort
ChiCTR2200065811Phase 4Recruiting
- Sponsor
- Department of Hematology, Peking Union Medical College Hospital
- Start
- Nov 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2b in polycythemia vera (PV), thrombocythemia and myeloproliferative disorder (MPD), sponsored by Department of Hematology, Peking Union Medical College Hospital. Primary endpoint: JAK2V617F variant allele frequency. Started Nov 2022; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
polycythemia vera (PV)thrombocythemiamyeloproliferative disorder (MPD)
Beyond the preview
Go deeper on ChiCTR2200065811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065811.